ImmuPharma (IMM) Reaches New 52-Week Low at $9.06

ImmuPharma PLC (LON:IMM) shares hit a new 52-week low during trading on Monday . The company traded as low as GBX 9.06 ($0.12) and last traded at GBX 9.28 ($0.12), with a volume of 313051 shares changing hands. The stock had previously closed at GBX 9.70 ($0.13).

Separately, Northland Securities reiterated a “corporate” rating on shares of ImmuPharma in a research note on Wednesday, September 26th.

ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at

ImmuPharma Company Profile (LON:IMM)

ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

Read More: Rule of 72

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with's FREE daily email newsletter.

Leave a Reply